

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

15 April 2021 (15.04.2021)



(10) International Publication Number

WO 2021/072156 A1

(51) International Patent Classification:

C07D 307/80 (2006.01) A61K 31/343 (2006.01)

C07D 307/81 (2006.01)

(21) International Application Number:

PCT/US2020/054922

(22) International Filing Date:

09 October 2020 (09.10.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/913,021 09 October 2019 (09.10.2019) US

(71) Applicant: BIOCRYST PHARMACEUTICALS, INC.

[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC 27703 (US).

(72) Inventors: KOTIAN, Pravin, L.; 1139 Magnolia Run,

Hoover, AL 35226 (US). BABU, Yarlagadda, S.;

4836 Southlake Parkway, Birmingham, AL 35244 (US).

ZHANG, Weihe; 2645 Manchester Court, Vestavia Hills,

AL 35226 (US). LU, Peng-Cheng; 1816 Altadena Ridge

Place, Vestavia Hills, AL 35243 (US). SPAULDING, An-

drew, E.; 3493 Hurricane Road, Hoover, AL 35226 (US).

WU, Minwan; 2709 Paden Trail, Vestavia Hills, AL 35226

(US). LV, Wei; 5373 Park Side Circle, Hoover, AL 35244

(US). NGUYEN, Trung, Xuan; 5066 Park Side Circle,

Hoover, AL 35244 (US). DANG, Zhao; 1226 Parliament

Lane, Vestavia Hills, AL 35216 (US). RAMAN, Krishnan;

3739 Spearman Drive, Birmingham, AL 35216 (US).

(74) Agent: GORDON, Dana, M. et al.; Foley Hoag LLP, Sea-

port West, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ORAL COMPLEMENT FACTOR D INHIBITORS

(57) Abstract: Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.



WO 2021/072156 A1